Novate Medical raises $12.4M investment

Ireland's Novate Medical has closed an €8.7 million ($12.4 million) round of investment led by Crédit Agricole Private Equity and Seroba Kernel Life Sciences. Existing investors ACT Venture Capital and Seroba Bioventures also participated in this round, according to the Irish Times.

Novate will use the investment for clinical trials and development of its lead medical device product. The five-year-old company has developed an inferior vena cava filter that prevents the development of pulmonary embolism during surgery. The condition affects more than 1.2 million people in the U.S. and Europe annually and may account for as many as half a million deaths. What makes Novate's offering so interesting is that it is biodegradable, eliminating the need for a secondary procedure to remove it.

Novate, which hopes to obtain regulatory sign-off for its product in the U.S. and the EU, employs 12 staff in Galway and another four at a sales operation in Britain.

- get more from the Irish Times
- see this WiredVC report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.